Martin J.S. Dyer

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 929 citations · Full text

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

G Hale, Mike Clark, R. Marcus et al. · The Lancet · 1988 · 692 citations

Lymphoid Neoplasia, Medicine, Immunology +5

Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types

Tony G. Willis, Dalal Jadayel, Ming‐Qing Du et al. · Cell · 1999 · 664 citations · Full text

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +7

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Thomas J. Kipps, Stephan Stilgenbauer et al. · Journal of Clinical Oncology · 2010 · 586 citations · Full text

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

Nathalie A. Johnson, Kerry J. Savage, Olga Ludkovski et al. · Blood · 2009 · 579 citations · Full text